## MEDP: Medpace Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 3.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($543.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)**
- Source: 富途牛牛 | 20251223T111017 | Neutral | Relevance: 100%
- This article estimates the intrinsic value of Medpace Holdings, Inc. (NASDAQ: MEDP) using a 2-stage Discounted Cash Flow (DCF) model and concluding it trades close to its estimated fair value of US$678. The analysis incorporates future cash flow forecasts and discusses key assumptions like the discount rate and growth phases. It also includes a brief SWOT analysis and advises investors to consider additional factors beyond valuation.

**2. Riverbridge Partners LLC Has $187.71 Million Stock Holdings in Medpace Holdings, Inc. $MEDP**
- Source: MarketBeat | 20251223T110918 | Neutral | Relevance: 100%
- ‌ Riverbridge Partners LLC decreased its stake in Medpace Holdings, Inc. by 15.9% in Q3, now holding 365,088 shares valued at approximately $187.7 million. Despite this, Medpace delivered strong Q3 earnings, surpassing expectations with EPS of $3.86 and revenue of $659.9 million, and issued optimistic FY2025 guidance. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $490.82, while insider selling has been observed in the last quarter.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $525 | $485 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.82M) |
| Sells | 29 ($217.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 8.4% (-4.4%)
- Vanguard Group Inc: 8.1% (-4.5%)
- AQR Capital Manageme: 3.6% (+65.1%)
- Wasatch Advisors LP: 3.3% (-2.1%)
- State Street Corpora: 2.4% (-4.8%)

### Key Risks

1. Heavy insider selling: $217M sold (29 transactions in 90 days).
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.60 signals overvaluation risk, limited margin of safety. Forward P/E 34.6x stretched relative to 9% growth. Quality metrics strong (ROE 74%, ROA 16%, margin 18%). Analyst sentiment positive (1 raises, avg +8%). Insider selling cluster ($217.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.1B |
| Beta | 1.43 |
| 52W Range | $250.05 - $626.25 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.60 |
| Forward P/E | 34.6 |
| Current P/E | 37.8 |
| YoY Growth | 9.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.0% to -0.1% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MACD histogram positive (1.14), confirming momentum. RSI neutral at 52. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.15% (CS: 70) | Neutral |
| RSI_14 | 51.8 | Neutral |
| MACD Histogram | 1.14 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 1.344x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $571.86
- **Stop Loss:** $543.10 (5.0% risk)
- **Target:** $600.62 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $23,446.26
- **Portfolio %:** 23.45%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-09 (Est: $4.21)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.57 | $3.86 | +8.1% |
| 2025Q2 | $3.00 | $3.10 | +3.5% |
| 2025Q1 | $3.07 | $3.67 | +19.6% |
| 2024Q4 | $3.12 | $3.68 | +18.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*